Quality of heart failure management: A comparison of care between a comprehensive heart failure program and a general cardiology practice

Congestive Heart Failure

Volumn 16, Issue 2, 2010, Pages 65-70

  Asghar, Hannah ^a   Rahko, Peter S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOLOGIST; CONTROLLED STUDY; DEFIBRILLATOR; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENERAL PRACTICE; HEALTH CARE QUALITY; HEALTH PROGRAM; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC PACING, ARTIFICIAL; CARDIOLOGY; CORONARY CARE UNITS; DEFIBRILLATORS, IMPLANTABLE; DIURETICS; FEMALE; GUIDELINE ADHERENCE; HEALTH STATUS INDICATORS; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; QUALITY OF HEALTH CARE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT; WISCONSIN;

EID: 77951742805     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2009.00136.x     Document Type: Article

References (38)

1. Heart Disease and Stroke Statistics - 2006 Update 2006, Dallas, TX, American Heart Association
2. Konstam MA, Rousseau MF, Kronenberg MW. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992, 86:431-438.
3. Flather MD, Yusuf S, Kober L. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000, 355:1575-1581.
4. Packer M, Bristow MR, Cohn JN. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349-1355.
5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
6. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
7. Pitt B, Zannad F, Remme WJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
8. Pfeffer MA, Swedberg K, Granger CB. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766.
9. Pfeffer MA, McMurray JJ, Velazquez EJ. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
10. Bigger JT, Fleiss JL, Kleiger R. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984, 69:250-258.
11. Buxton AE, Marchlinski FE, Waxman HL. Prognostic factors in nonsustained ventricular tachycardia. Am J Cardiol 1984, 53:1275-1279.
12. Moss AJ, Hall WJ, Cannom DS. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996, 335:1933-1940.
13. Moss AJ, Zareba W, Hall WJ. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346:877-883.
14. Bardy GH, Lee KL, Mark DB. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352:225-237.
15. Kadish A, Dyer A, Daubert JP. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004, 350:2151-2158.
16. Cleland JG, Daubert JC, Erdmann E. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005, 352:1539-1549.
17. Cazeau S, Leclercq C, Lavergne T. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001, 344:873-880.
18. Young JB, Abraham WT, Smith AL. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003, 289:2685-2694.
19. Bristow MR, Saxon LA, Boehmer J. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004, 350:2140-2150.
20. Bonow RO, Bennett S, Casey DE. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America. J Am Coll Cardiol 2005, 46:1144-1178.
21. Fonarow GC, Yancy CW, Heywood JT. Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE Registry. Arch Intern Med 2005, 165:1469-1477.
22. Fonarow GC, Abraham WT, Albert NM. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 2007, 297:61-70.
23. Hunt SA, Abraham WT, Chin MH. Circulation 2005, 112:e154-e235. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure)
24. Cintron G, Bigas C, Linares E. Nurse practitioner role in a chronic congestive heart failure clinic: in-hospital time, costs, and patient satisfaction. Heart Lung 1983, 12:237-240.
25. Rich MW, Beckham V, Wittenberg C. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995, 333:1190-1195.
26. McAlister FA, Lawson FM, Teo KK. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001, 110:378-384.
27. Shah NB, Der E, Ruggerio C. Prevention of hospitalizations for heart failure with an interactive home monitoring program. Am Heart J 1998, 135:373-378.
28. Koshman SL, Charrois TL, Simpson SH. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med 2008, 168:687-694.
29. Gattis WA, Hasselblad V, Whellan DJ. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med 1999, 159:1939-1945.
30. Velez M, Westerfeldt B, Rahko PS. Why it pays for hospitals to initiate a heart failure disease management program. Dis Manag Health Outcomes 2008, 16:155-173.
31. Lee DS, Tu JV, Juurlink DN. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 2005, 294:1240-1247.
32. Schoeller R, Andresen D, Buttner P. First- or second-degree atrioventricular block as a risk factor in idiopathic dilated cardiomyopathy. Am J Cardiol 1993, 71:720-726.
33. Aaronson KD, Schwartz JS, Chen TM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997, 95:2660-2667.
34. Farwell D, Patel NR, Hall A. How many people with heart failure are appropriate for biventricular resynchronization? Eur Heart J 2000, 21:1246-1250.
35. Ho PM, Spertus JA, Masoudi FA. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006, 166:1842-1847.
36. Gattis WA, O'Connor CM, Gallup DS. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004, 43:1534-1541.
37. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007, 297:177-186.
38. Gonseth J, Guallar-Castillon P, Banegas JR. The effectiveness of disease management programmes in reducing hospital re-admission in older patients with heart failure: a systematic review and meta-analysis of published reports. Eur Heart J 2004, 25:1570-1595.